ArticleMicrobial cell factories2025
Engineering the oleaginous yeast Yarrowia lipolytica for co-production of phenolic monoterpenes thymol and carvacrol.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic engineering strategies: utilizing different microbial strains and advanced technologies for the synthesis of high-valued terpenoids.Antonie van Leeuwenhoek · 2026Review
- Thymol: properties, synthesis, mechanism of action, and applications.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThymol and carvacrol are natural phenolic compounds with various biological activities. They are widely used in the spice and medicine industries. Production of thymol and carvacrol using microbial cell factories is considered a viable alternative to extracting them from plants of the Thymus genus or the Lamiaceae family.
resultsIn this study, the complete synthetic pathways of thymol and carvacrol were constructed using the oleaginous yeast Yarrowia lipolytica Po1f as a chassis. The total titer of thymol and carvacrol was increased 18.44-fold by enhancing the mevalonate pathway during the modification process and reducing the metabolic flux from geranyl diphosphate (GPP) to farnesyl diphosphate (FPP) through the modification of ERG20. Next, by increasing the copy number of the TvCYP71D507 gene combination (TvCYP71D507 + TvTPS2 + TvSDR1) in the synthetic pathway, the total titer was increased by 1.75-fold. Finally, the engineered strain CT18, which was reintroduced the 3-isopropylmalate dehydrogenase (LEU2) gene, achieved a titer of thymol and carvacrol of 7.14 mg/L in shake flasks and 61.31 mg/L in a 5-L bioreactor.
conclusionThis study demonstrates the de novo synthesis of thymol and carvacrol in Y. lipolytica for the first time and provides a valuable reference for constructing microbial cell factories for phenolic monoterpenes biosynthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.